- Home
- KURA vs CTO Comparison
KURA vs CTO Comparison
Compare KURA & CTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KURA | CTO |
|---|---|---|
| Founded | 2014 | 1902 |
| Country | United States | United States |
| Employees | N/A | 42 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 841.6M | 695.9M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | KURA | CTO |
|---|---|---|
| Price | $10.40 | $22.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | ★ $25.56 | $22.50 |
| AVG Volume (30 Days) | ★ 1.4M | 321.3K |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 7.44% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,482,000.00 | N/A |
| Revenue This Year | $28.28 | $7.63 |
| Revenue Next Year | $106.37 | $2.76 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.24 | N/A |
| 52 Week Low | $5.45 | $15.07 |
| 52 Week High | $12.49 | $22.66 |
Technical Indicators
Market Signals| Indicator | KURA | CTO |
|---|---|---|
| Relative Strength Index (RSI) | 45.63 | 60.41 |
| Support Level | $8.53 | $17.79 |
| Resistance Level | $10.97 | $22.66 |
| Average True Range (ATR) | 0.47 | 0.40 |
| MACD | -0.17 | -0.00 |
| Stochastic Oscillator | 10.29 | 73.14 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.